CACNA1C mutation as a prognosis predictor of immune checkpoint inhibitor in skin cutaneous melanoma.
暂无分享,去创建一个
Jian Zhang | P. Luo | Anqi Lin | T. Gu | Shuang Hou | Yushan Huang | Jiarong Yao
[1] Zi-Ming Wang,et al. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma , 2023, Journal of thoracic disease.
[2] H. Körner,et al. Tumor Necrosis Factor: What Is in a Name? , 2022, Cancers.
[3] B. Zeng,et al. Human cancer cells generate spontaneous calcium transients and intercellular waves that modulate tumor growth. , 2022, Biomaterials.
[4] Yongting Luo,et al. The Regulatory Roles of Mitochondrial Calcium and the Mitochondrial Calcium Uniporter in Tumor Cells , 2022, International journal of molecular sciences.
[5] Alexander M. Wathen,et al. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. , 2022, Cellular signalling.
[6] J. Marsh,et al. Diverse Molecular Mechanisms Underlying Pathogenic Protein Mutations: Beyond the Loss-of-Function Paradigm. , 2022, Annual review of genomics and human genetics.
[7] P. Murray,et al. Calcium-dependent signalling in B-cell lymphomas , 2021, Oncogene.
[8] R. Houlgatte,et al. Integrative genomics analysis of nasal intestinal-type adenocarcinomas demonstrates the major role of CACNA1C and paves the way for a simple diagnostic tool in male woodworkers , 2021, Clinical epigenetics.
[9] Xiaohan Chang,et al. CACNA1C is a prognostic predictor for patients with ovarian cancer , 2021, Journal of Ovarian Research.
[10] Jian Zhang,et al. Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma , 2021, Frontiers in Molecular Biosciences.
[11] D. Bello,et al. Adjuvant immunotherapy for melanoma , 2021, Journal of surgical oncology.
[12] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[13] M. Mercogliano,et al. Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy , 2021, Cancers.
[14] Qiong Zhang,et al. Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response , 2020, Briefings Bioinform..
[15] Aleksandra A. Kolodziejczyk,et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy , 2020, Nature Cell Biology.
[16] Shijun Kang,et al. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer , 2020, Cancer Immunology, Immunotherapy.
[17] Takashi Ando,et al. Aspirin Induces Mitochondrial Ca2+ Remodeling in Tumor Cells via ROS‒Depolarization‒Voltage-Gated Ca2+ Entry , 2020, International journal of molecular sciences.
[18] Jin-liang Wang,et al. Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer , 2020, Targeted Oncology.
[19] L. Fu,et al. The immune landscape of esophageal cancer , 2019, Cancer communications.
[20] A. Scarpa,et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] R. Xu,et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? , 2019, Cancer communications.
[22] E. V. Van Allen,et al. Genomic correlates of response to immune checkpoint blockade , 2019, Nature Medicine.
[23] A. Richmond,et al. Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy , 2019, Front. Immunol..
[24] C. Brennan,et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.
[25] S. M. Toor,et al. Immune checkpoint inhibitors: recent progress and potential biomarkers , 2018, Experimental & Molecular Medicine.
[26] T A Chan,et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] Yassen Assenov,et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.
[28] G. Getz,et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors , 2018, Nature Genetics.
[29] Dai Fukumura,et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.
[30] R. Kerbel,et al. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa , 2018, Nature Reviews Clinical Oncology.
[31] Betty Y. S. Kim,et al. Improving immune–vascular crosstalk for cancer immunotherapy , 2018, Nature Reviews Immunology.
[32] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[33] Y. Kienast,et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade , 2017, Science Translational Medicine.
[34] K. Flaherty,et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma , 2017, Nature Reviews Clinical Oncology.
[35] K. Martin,et al. Altering calcium influx for selective destruction of breast tumor , 2017, BMC Cancer.
[36] P. A. Futreal,et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance , 2017, Science Translational Medicine.
[37] P. Laurent-Puig,et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.
[38] Roland Eils,et al. Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..
[39] Gianluca Bontempi,et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.
[40] S. Turley,et al. Immunological hallmarks of stromal cells in the tumour microenvironment , 2015, Nature Reviews Immunology.
[41] J. Wolchok,et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] G. Coukos,et al. Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors , 2014, Nature Medicine.
[43] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[44] Rui-Ru Ji,et al. An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.
[45] Douglas Hanahan,et al. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .
[46] Eli Gilboa,et al. The determinants of tumour immunogenicity , 2012, Nature Reviews Cancer.
[47] S. Quezada,et al. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma , 2008, The Journal of experimental medicine.
[48] A. Scharenberg,et al. Calcium signalling and cell-fate choice in B cells , 2007, Nature Reviews Immunology.
[49] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[50] F. D. de Gruijl,et al. Predictions of skin cancer incidence in the Netherlands up to 2015 , 2005, The British journal of dermatology.
[51] J. Wilde,et al. Rituxan (anti‐CD20 antibody)‐induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis , 2005, Clinical and experimental immunology.
[52] OUP accepted manuscript , 2022, Briefings In Bioinformatics.
[53] R. Scolyer,et al. Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.
[54] Bruce K Armstrong,et al. Clinical Features Associated With Individuals at Higher Risk of Melanoma: A Population-Based Study , 2017, JAMA dermatology.
[55] P. Gimotty,et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy , 2008, Nature Medicine.